S&P 500   4,565.33 (+0.23%)
DOW   35,544.39 (+0.36%)
QQQ   391.17 (+0.25%)
AAPL   189.57 (-0.44%)
MSFT   379.15 (-0.93%)
META   333.77 (-1.54%)
GOOGL   135.59 (-1.17%)
AMZN   146.67 (-0.24%)
TSLA   247.27 (+0.22%)
NVDA   481.56 (+0.70%)
NIO   7.24 (+0.42%)
BABA   74.95 (-2.33%)
AMD   124.43 (+1.98%)
T   16.26 (+0.49%)
F   10.62 (+2.41%)
MU   77.04 (+1.21%)
CGC   0.57 (+4.57%)
GE   119.07 (+0.19%)
DIS   92.81 (+0.34%)
AMC   7.15 (+6.72%)
PFE   30.06 (+1.25%)
PYPL   58.63 (+0.27%)
XOM   103.46 (-0.42%)
S&P 500   4,565.33 (+0.23%)
DOW   35,544.39 (+0.36%)
QQQ   391.17 (+0.25%)
AAPL   189.57 (-0.44%)
MSFT   379.15 (-0.93%)
META   333.77 (-1.54%)
GOOGL   135.59 (-1.17%)
AMZN   146.67 (-0.24%)
TSLA   247.27 (+0.22%)
NVDA   481.56 (+0.70%)
NIO   7.24 (+0.42%)
BABA   74.95 (-2.33%)
AMD   124.43 (+1.98%)
T   16.26 (+0.49%)
F   10.62 (+2.41%)
MU   77.04 (+1.21%)
CGC   0.57 (+4.57%)
GE   119.07 (+0.19%)
DIS   92.81 (+0.34%)
AMC   7.15 (+6.72%)
PFE   30.06 (+1.25%)
PYPL   58.63 (+0.27%)
XOM   103.46 (-0.42%)
S&P 500   4,565.33 (+0.23%)
DOW   35,544.39 (+0.36%)
QQQ   391.17 (+0.25%)
AAPL   189.57 (-0.44%)
MSFT   379.15 (-0.93%)
META   333.77 (-1.54%)
GOOGL   135.59 (-1.17%)
AMZN   146.67 (-0.24%)
TSLA   247.27 (+0.22%)
NVDA   481.56 (+0.70%)
NIO   7.24 (+0.42%)
BABA   74.95 (-2.33%)
AMD   124.43 (+1.98%)
T   16.26 (+0.49%)
F   10.62 (+2.41%)
MU   77.04 (+1.21%)
CGC   0.57 (+4.57%)
GE   119.07 (+0.19%)
DIS   92.81 (+0.34%)
AMC   7.15 (+6.72%)
PFE   30.06 (+1.25%)
PYPL   58.63 (+0.27%)
XOM   103.46 (-0.42%)
S&P 500   4,565.33 (+0.23%)
DOW   35,544.39 (+0.36%)
QQQ   391.17 (+0.25%)
AAPL   189.57 (-0.44%)
MSFT   379.15 (-0.93%)
META   333.77 (-1.54%)
GOOGL   135.59 (-1.17%)
AMZN   146.67 (-0.24%)
TSLA   247.27 (+0.22%)
NVDA   481.56 (+0.70%)
NIO   7.24 (+0.42%)
BABA   74.95 (-2.33%)
AMD   124.43 (+1.98%)
T   16.26 (+0.49%)
F   10.62 (+2.41%)
MU   77.04 (+1.21%)
CGC   0.57 (+4.57%)
GE   119.07 (+0.19%)
DIS   92.81 (+0.34%)
AMC   7.15 (+6.72%)
PFE   30.06 (+1.25%)
PYPL   58.63 (+0.27%)
XOM   103.46 (-0.42%)

Galmed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:GLMD)

$0.36
-0.01 (-1.37%)
(As of 01:16 PM ET)
Compare
Today's Range
$0.34
$0.38
50-Day Range
$0.29
$0.66
52-Week Range
$0.26
$14.18
Volume
163,309 shs
Average Volume
133,266 shs
Market Capitalization
$604,800.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GLMD stock logo

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Stock Price History

GLMD Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Galmed Pharmaceuticals Ltd GLMD
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
GLMD Galmed Pharmaceuticals Ltd.
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/01/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
4
Year Founded
N/A

Profitability

Net Income
$-17,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.20 per share

Miscellaneous

Free Float
1,347,000
Market Cap
$609,840.00
Optionable
Not Optionable
Beta
0.95
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Allen Baharaff (Age 58)
    Co-Founder, President, CEO & Chairman
    Comp: $803.5k
  • Mr. Doron Cohen (Age 56)
    Chief Financial Officer
    Comp: $175.33k
  • Mr. Guy Nehemya (Age 38)
    COO & Data Protection Officer
    Comp: $235.56k
  • Mr. Yohai Stenzler CPA (Age 40)
    Chief Accounting Officer
    Comp: $239.48k
  • Dr. Liat Hayardeny (Age 56)
    Chief Scientific Officer
    Comp: $125.24k
  • Ms. Yael Hollander (Age 40)
    Vice President of Legal Affairs & Strategy
    Comp: $134.21k
  • Ms. Shani Ganon
    Human Resources Manager
  • Dr. Tali Gorfine (Age 53)
    Medical Consultant
    Comp: $202.76k














GLMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares.
View GLMD analyst ratings
or view top-rated stocks.

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $7.50 at the beginning of the year. Since then, GLMD shares have decreased by 95.2% and is now trading at $0.3630.
View the best growth stocks for 2023 here
.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 12,900 shares, an increase of 17.3% from the October 31st total of 11,000 shares. Based on an average trading volume of 165,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short.
View Galmed Pharmaceuticals' Short Interest
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (14.87%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GLMD) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -